Rheumatology

Melanoma/Skin Cancer

Questions discussed in this category

How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?

Given the improvement in liver function, what factors should be considered before reinitiating immunotherapy?"

4 Answers available

What biologics would you use in a patient with rheumatoid arthritis who developed multiple basal cell carcinomas requiring Mohs surgery while on a TNF-inhibitor and did not respond to rituximab?

Would you switch to a biologic with a different mechanism of action and if so, what options would you consider?

2 Answers available

What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?

2 Answers available

Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?

2 Answers available

What immunosuppressive agents would be available to patients with a history of melanoma?

Would you use immunosuppression in patients several years after curative treatment for melanoma?

1 Answer available

Would you avoid the use of a TNF inhibitors in patients with a remote history of melanoma, including those with ocular melanoma?

1 Answer available

Papers discussed in this category

Cancer cell, 2022 May 09

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.

Cancer chemotherapy and pharmacology, 2019 Aug 23

Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.

Related Topics in Rheumatology